Aggressive Lymphomas
Feature
Decline in non-Hodgkin lymphoma deaths to continue in 2018
The estimated mortality is highest in Maine and West Virginia, lowest in Utah.
Conference Coverage
Combo is preferentially active in T-cell lymphomas
LA JOLLA, CA—A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a...
Conference Coverage
TRANSCEND NHL trial identifies window
for CAR T expansion
SAN FRANCISCO – The study shows a correlation between certain patient characteristics and outcomes with the CAR T-cell therapy JCAR017.
News
In situ vaccination eradicates lymphoma, other cancers
Experiments in mice have shown that injecting immune-stimulating agents directly into a tumor can help the immune system eradicate tumors in other...
News
Combo could treat double-hit lymphoma
Existing drugs could be combined to treat double-hit lymphoma (DHL), according to preclinical research published in Science Translational Medicine...
From the Journals
Checkpoint inhibitors look safe in rheumatology patients
The Mayo Clinic analysis examines 16 patients with rheumatologic diseases and cancer who received checkpoint inhibitor therapy.
News
Risks of MGUS persist beyond 30 years
A long-term study showed that patients with monoclonal gammopathy of undetermined significance (MGUS) were still at risk of progressing to other...
News
CAR T-cell therapy on fast track in US, EU
The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah, formerly CTL019) is getting fast-tracked in the United States (US)...
News
FDA grants priority review to CAR T-cell therapy for DLBCL
The application for tisagenlecleucel suspension is based on results from the phase 2 JULIET trial.
News
Generic bortezomib available in US
Fresenius Kabi has introduced its generic version of Velcade, Bortezomib for Injection, to the US market. This is the first intravenous...
Conference Coverage
AUDIO: Immunotherapy’s role in NHL
Dr. Stephen Ansell outlines the challenges in using immunotherapy effectively in non-Hodgkin lymphoma and future directions.